On May 15, 2025, HC Wainwright & Co. reaffirmed its positive outlook on CalciMedica (CALC, Financial) by reiterating a 'Buy' rating. Analyst Joseph Pantginis continues to express confidence in the biotech firm, maintaining the price target at $16.00 USD.
This consistent rating and price target reflect a steady sentiment towards CalciMedica's market position and future prospects. The price target remains unchanged from the prior evaluation, indicating sustained belief in the company's strategic direction and growth potential.
Investors and market observers should note that the reiterated 'Buy' rating and maintained price target signal potential opportunities amidst the evolving biotech landscape. CalciMedica (CALC, Financial) remains a notable stock to watch as it navigates the competitive market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for CalciMedica Inc (CALC, Financial) is $16.00 with a high estimate of $20.00 and a low estimate of $13.00. The average target implies an upside of 736.38% from the current price of $1.91. More detailed estimate data can be found on the CalciMedica Inc (CALC) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, CalciMedica Inc's (CALC, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
